

The use of Midodrine as an Adjunctive Therapy to Liberate Patients from Intravenous Vasopressors: A Systematic Review and Meta-Analysis of Randomized Controlled Studies

Mohamed Hamed, MD ^a, Sheref A. Elseidy, MD ^b, Ahmed Elkheshen, MD ^c, Jamal Maher, MD ^d, Adel Elmoghrabi, MD ^e, Ahmed Zaghloul, MD ^f, Andrew Panakos, MD ^g, Sidakpal Panaich, MD ^f, Marwan Saad, MD, PhD ^{hi}, Ayman Elbadawi, MD ^k

^a Department of Internal Medicine, Florida Atlantic University, Boca Raton, FL

^b Department of Internal Medicine, Rochester General Hospital, Rochester, NY

^c Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX

^d Section of Cardiology, Baylor College of Medicine, Houston, TX

^e Division of Cardiology, Wayne State University/Detroit Medical Center, Detroit, MI

^f Division of Cardiology, University of Iowa Health Care, Iowa, IA

^g Division of Cardiology, Florida Atlantic University, Boca Raton, FL

^h Lifespan Cardiovascular Institute, Providence, RI

ⁱ Department of Medicine, Division of Cardiology, Warren Alpert Medical School of Brown University, Providence, RI

^k Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX

Word count: 2,500

Keywords: midodrine; vasopressors, vasopressor; shock; intensive care unit; ICU; critical care

Corresponding author:

Ayman Elbadawi, MD,
Division of Cardiology
University of Texas Southwestern Medical Center
5323 Harry Hines Blvd, Dallas, TX 75390-9047
Email: aymangalal24@hotmail.com



PRISMA 2020 Checklist

Supplementary Table 1

Section and Topic	Item#	Checklist item	Pages where item is reported
TITLE			
Title	1	Identify the report as a metanalysis.	1
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	2-3
INTRODUCTION			
Overview	3	Overview on the recent data and current evidence	3-4
Rationale	4	Describe the rationale for the review in the context of existing knowledge.	4
Objectives	5	Provide a clear statement of the objectives of the review	4
METHODS			
Data sources and Search strategy	6	Provide the full search strategies for all databases, websites, scientific sessions including search terms used.	4-5
Eligibility criteria	7	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	5
Data collection process	8	Specify the number of investigators and data extracted, whether they work independently, and the process of confirming data from study investigators	5
Outcomes	9	Identify the Primary and Secondary outcomes including definition of endpoints	5-6
Study risk of bias assessment	10	Provides how risk of bias was evaluated in the included studies and the criteria used in the evaluation	6
Statistical analysis	11	Describe methods used to synthesize results, presence and degree of heterogeneity and the software package used in the analysis	6
Certainty assessment	12	Describe methods used to assess certainty for outcomes	6
RESULTS			
Study selection	13	Describe the results of the search and selection process from the number of identified from the search to the number of studies included in the review and it is included in a flow diagram	Page 7, Figure 1
Study characteristics	14	Cite each included study and present its characteristics	7
Risk of bias in included studies	15	Provides assessments of risk of bias for each included study	7
Outcomes	16	Provides primary and secondary outcomes using appropriate structured tables or plots.	7-8



PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
DISCUSSION			
Discussion	17a	Provide a general interpretation of the results	8-9
	17b	Discuss the rationale of the study	9
	17c	Compare the review to previously published studies and their limitations. It also provides an explanation on the importance of this review in overcoming those limitations.	10
	17d	Describe possible reasons of the review outcomes by providing previous evidence.	10-11
	17e	Discuss implications of the review results in current practice and future research.	11
Limitations			
Limitations	18	Discuss possible limitations of adjuvant midodrine use with IV vasopressors in resolving shock	11
Conclusion			
Conclusion	19	Summarize review outcome	12
OTHER INFORMATION			
Registration and protocol	20	Provided registration information of the review and how to assess review protocol	5

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

For more information, visit: <http://www.prisma-statement.org/>


Supplementary Table 2: Risk of bias of the individual studies by Cochrane risk assessment tool

	Costa-Pinto (MAVERICK)	El Adly	Ali	Santer (MIDAS)
Random sequence generation (<i>Selection bias</i>)				
Allocation concealment (<i>Selection bias</i>)				
Blinding of participants and personnel (<i>Performance bias</i>)				
Blinding of outcome assessment (<i>Detection bias</i>)				
Incomplete outcome data (<i>Attrition bias</i>)				
Selective reporting (<i>Reporting bias</i>)				
Other sources of bias				


= Low risk of bias
 = Risk of bias
 = Unclear

Supplementary Figure 1

Total IV vasopressor time excluding Ali et al.



Total IV vasopressor time excluding Ali et al. and El Adly et al.



Total IV vasopressor time excluding Santer et al.

